MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment

// Chunyan Gu 1, 2, 4, * , Lang Feng 3, 5, * , Hailin Peng 7, * , Hongbao Yang 8 , Zhenqing Feng 1 , Ye Yang 2, 6 1 Department of Pathology, Nanjing Medical University, 210029, Nanjing, China 2 Basic Medical College, Nanjing University of Chinese Medicine, 210046, Nanjing, China 3 Department of Urology, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China 4 Department of Pathology, University of Iowa Carver College of Medicine, 52242, Iowa City, IA, USA 5 Department of Urology, University of Iowa Carver College of Medicine, 52242, Iowa City, IA, USA 6 Department of Internal Medicine, University of Iowa Carver College of Medicine, 52242, Iowa City, IA, USA 7 Department of Laboratory Medicine, Taizhou people's hospital, 225300, Taizhou, China 8 Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China * These authors have contributed equally to this work Correspondence to: Feng Zhenqing, e-mail: fengzhenqing@njmu.edu.cn Ye Yang, e-mail: yangye876@sina.com Keywords: multiple myeloma, metadherin (MTDH), oncogene, Bortezomib, MMSET (WHSC1) Received: September 13, 2015      Accepted: November 26, 2015      Published: December 14, 2015 ABSTRACT Metadherin (MTDH) is identified as an oncogene in multiple cancers including breast cancer, bladder cancer and endometrial cancer. However, the function of MTDH in multiple myeloma (MM) is still unexplored. In this study, we disclose that MTDH is an oncogene in MM. This is characterized by an elevation mRNA level of MTDH and chromosomal gain of MTDH locus in MM cells compared to normal samples. Moreover, MTDH expression significantly increased in MMSET translocation (MS) subgroup, one of the high-risk subgroups in MM, and was significantly correlated with MM patients’ poor outcomes in Total Therapy 2 (TT2) cohort. Further knockdown of MTDH expression by shRNA in MM cells induced cell apoptosis, inhibited MM cells growth in vitro and decreased xenograft tumor formation in vivo . Interestingly, opposite to TT2, MM patients with high-MTDH expression showed favorable survival outcomes in the TT3 cohort, while Bortezomib treatment was the major difference between TT2 and TT3 cohort. Furthermore we proved that Bortezomib suppressed pre- and post-transcription levels of MTDH expression of MM cells in vitro and in vivo . Finally, our studies demonstrated that MTDH is a transcriptional gene of MMSET/NFκB /MYC signaling in MM cells, which is inhibited by Bortezomib treatment.